Idorsia has entered into exclusive negotiations with regard to a prospective
strategic transaction for its Asia Pacific (ex-China) operations for up to CHF
400 million
Ad hoc announcement pursuant to Art. 53 LR
Allschwil, Switzerland – June 06 , 2023
Idorsia Ltd (SIX: IDIA) today announced that it has entered into exclusive
negotiations with an undisclosed party regarding its operating businesses in
the Asia Pacific (ex-China) region, including selected license rights to
products from Idorsia’s portfolio in those territories, for a total
consideration of up to CHF 400 million.
This prospective strategic transaction is subject to completion of
satisfactory due diligence and legal documentation. Further announcements will
be made as appropriate.
André C. Muller, Chief Financial Officer of Idorsia, add ed :
“This prospective strategic transaction would allow Idorsia to realize the
significant value we have created in the region, and would extend our cash
runway, while maintaining relationships for the future development and
commercialization of our pipeline programs in the region. I would expect the
potential transaction to be completed during July, subject to completion of
satisfactory due diligence and legal documentation.”
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – We have more ideas, we see more
opportunities and we want to help more patients. In order to achieve this, we
will develop Idorsia into a leading biopharmaceutical company, with a strong
scientific core.
Headquartered near Basel, Switzerland – a European biotech-hub – Idorsia is
specialized in the discovery, development and commercialization of small
molecules to transform the horizon of therapeutic options. Idorsia has a
20-year heritage of drug discovery, a broad portfolio of innovative drugs in
the pipeline, an experienced team of professionals covering all disciplines
from bench to bedside, and commercial operations in Europe, Japan, and the US –
the ideal constellation for bringing innovative medicines to patients.
Idorsia was listed on the SIX Swiss Exchange (ticker symbol: IDIA) in June
2017 and has over 1,300 highly qualified specialists dedicated to realizing our
ambitious targets.
For further information, please contact
Andrew C. Weiss
Senior Vice President, Head of Investor Relations & Corporate Communications
Idorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil
+41 58 844 10 10
investor.relations@idorsia.com
media.relations@idorsia.com
www.idorsia.com
The above information contains certain 'forward-looking statements', relating
to the company's business, which can be identified by the use of
forward-looking terminology such as 'estimates', 'believes', 'expects', 'may',
'are expected to', 'will', 'will continue', 'should', 'would be', 'seeks',
'pending' or 'anticipates' or similar expressions, or by discussions of
strategy, plans or intentions. Such statements include descriptions of the
company's investment and research and development programs and anticipated
expenditures in connection therewith, descriptions of new products expected to
be introduced by the company and anticipated customer demand for such products
and products in the company's existing portfolio. Such statements reflect the
current views of the company with respect to future events and are subject to
certain risks, uncertainties and assumptions. Many factors could cause the
actual results, performance or achievements of the company to be materially
different from any future results, performances or achievements that may be
expressed or implied by such forward-looking statements. Should one or more of
these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those described herein
as anticipated, believed, estimated or expected.
Anhang Medienmitteilung PDF
